Skip to main content
Top
Gepubliceerd in: Quality of Life Research 5/2009

01-06-2009

How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses

Auteurs: Peter M. Fayers, Madeleine T. King

Gepubliceerd in: Quality of Life Research | Uitgave 5/2009

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Excerpt

In 1988 the Lancet published a very large randomised clinical trial of intravenous streptokinase, oral aspirin, both, or neither for treatment of suspected acute myocardial infarction [1]. The ISIS-2 trial recruited 17,187 patients from 417 hospitals. The authors concluded that there were benefits both from streptokinase and from aspirin. This paper contained a complex table reporting subgroup analyses, and rather intriguingly, the first analysis was by astrological birth sign. The results suggested that for people born under the star signs Gemini and Libra, aspirin was no better than placebo; for others, aspirin had a strongly beneficial effect. Why, one might wonder, did a highly respected journal publish such arrant nonsense? …
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, ii, 349–360. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet, ii, 349–360.
2.
go back to reference Bland, J. M., & Altman, D. G. (1995). Multiple significance tests: The Bonferroni method. British Medical Journal, 310, 170.PubMed Bland, J. M., & Altman, D. G. (1995). Multiple significance tests: The Bonferroni method. British Medical Journal, 310, 170.PubMed
6.
go back to reference Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology, 57, 229–236. doi:10.1016/j.jclinepi.2003.08.009.PubMedCrossRef Brookes, S. T., Whitely, E., Egger, M., Smith, G. D., Mulheran, P. A., & Peters, T. J. (2004). Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test. Journal of Clinical Epidemiology, 57, 229–236. doi:10.​1016/​j.​jclinepi.​2003.​08.​009.PubMedCrossRef
9.
go back to reference Yusuf, S., Wittes, J., Probstfield, J., & Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. Journal of the American Medical Association, 266, 93–98. doi:10.1001/jama.266.1.93.PubMedCrossRef Yusuf, S., Wittes, J., Probstfield, J., & Tyroler, H. A. (1991). Analysis and interpretation of treatment effects in subgroups of patients in randomised clinical trials. Journal of the American Medical Association, 266, 93–98. doi:10.​1001/​jama.​266.​1.​93.PubMedCrossRef
10.
go back to reference Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001). Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technology Assessment, 5(33), 1–56. From http://www.hta.nhs.uk/fullmono/mon533.pdf. Accessed 12 March 2009. Brookes, S. T., Whitley, E., Peters, T. J., Mulheran, P. A., Egger, M., & Davey Smith, G. (2001). Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positives and false-negatives. Health Technology Assessment, 5(33), 1–56. From http://​www.​hta.​nhs.​uk/​fullmono/​mon533.​pdf. Accessed 12 March 2009.
11.
12.
go back to reference Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007). Statistics in medicine—reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 357, 2189–2194. doi:10.1056/NEJMsr077003.PubMedCrossRef Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007). Statistics in medicine—reporting of subgroup analyses in clinical trials. The New England Journal of Medicine, 357, 2189–2194. doi:10.​1056/​NEJMsr077003.PubMedCrossRef
13.
go back to reference Martin, V., Cady, R., Mauskop, A., Seidman, L. S., Rodgers, A., Hustard, C. M., et al. (2008). Efficacy of rizatriptan for menstrual migraine in an early intervention model: A prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache, 48, 226–235.PubMedCrossRef Martin, V., Cady, R., Mauskop, A., Seidman, L. S., Rodgers, A., Hustard, C. M., et al. (2008). Efficacy of rizatriptan for menstrual migraine in an early intervention model: A prospective subgroup analysis of the rizatriptan TAME (Treat a Migraine Early) studies. Headache, 48, 226–235.PubMedCrossRef
Metagegevens
Titel
How to guarantee finding a statistically significant difference: the use and abuse of subgroup analyses
Auteurs
Peter M. Fayers
Madeleine T. King
Publicatiedatum
01-06-2009
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 5/2009
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-009-9473-3

Andere artikelen Uitgave 5/2009

Quality of Life Research 5/2009 Naar de uitgave